Canada Preclinical Imaging Market (2024-2029)
The Canada Preclinical Imaging Market was valued at $20.2 Million in 2024 and projected to reach to $25.2 Million by 2029, representing a compound annual growth rate of 4.5%. Canada's preclinical imaging market demonstrates steady expansion driven by substantial government funding for biomedical research and increasing modernization of laboratory facilities.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada Preclinical Imaging Market Trends and Insights
- This steady growth reflects Canada's robust investment in biomedical research infrastructure and the increasing adoption of advanced imaging technologies across academic institutions and pharmaceutical research facilities.
- Canada's commitment to life sciences innovation and government funding for research initiatives continues to drive demand for preclinical imaging solutions. The Canadian preclinical imaging sector benefits from a strong regulatory environment and collaboration between universities, research hospitals, and private sector organizations.
- Canada's position as a leader in drug discovery and development has created sustained demand for sophisticated imaging modalities used in early-stage research.
- Between 2024 and 2029, Canada is expected to see increased adoption of multimodal imaging systems and enhanced imaging software platforms that support translational research pathways..
Key Market Statistics
- CAGR (2024-2029) 4.5% CAGR
- Market Size, 2024 ~USD 20.2 Million
- Forecast, 2029 ~USD 25.2 Million
- Country Canada
Canada Preclinical Imaging Market Overview
Market Valuation :
Canada's preclinical imaging market is valued at $20.2 million in 2024, with projections reaching $25.2 million by 2029, representing a steady 4.5% CAGR.
Research Infrastructure Investment :
Canada's robust investment in biomedical research infrastructure, including funding from CIHR and NSERC, drives adoption of advanced preclinical imaging technologies across institutions.
Academic and Pharma Adoption :
Increasing adoption of preclinical imaging technologies across Canadian academic institutions, research hospitals, and pharmaceutical research facilities accelerates market growth.
Growth Trajectory :
At 4.5% CAGR, Canada's market growth slightly lags the global 5% rate, reflecting regional research priorities and funding cycles specific to the Canadian healthcare landscape.
Canada Preclinical Imaging Market Dynamics
- Academic research centers and pharmaceutical companies are progressively integrating advanced imaging modalities such as micro-CT, MRI, and optical imaging to enhance drug development pipelines and accelerate translational research initiatives. The market outlook remains positive as Canadian institutions prioritize competitive research capabilities and collaborate with international partners.
- Continued investment in life sciences infrastructure, coupled with growing demand for non-invasive imaging solutions in preclinical studies, positions Canada for sustained market growth through 2029.
- Regional regulatory support and talent retention in research sectors further strengthen market fundamentals..
Market Ecosystem
Related Ecosystem
Diagnostic Imaging
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT)
- CT Scanners
- Nuclear Imaging
- Positron Emission Tomography
- Siemens healthineers
- PHILIPS HEALTHCARE
- CANON INC.
- FUJIFILM Holdings Corporation
- UNITED IMAGING HEALTHCARE CO., LTD.
Medical Devices
- Polymerase Chain Reaction (PCR)
- Magnetic Resonance Imaging (MRI)
- Disposable Autoinjectors
- Pulse Oximeters
- Blood Pressure Monitors
- Medtronic plc
- Abbott Laboratories
- Stryker Corporation
- Becton, Dickinson and Company
- CONMED Corporation
Key Takeaways
- Canada's preclinical imaging market is valued at $20.2 million in 2024 with a projected value of $25.2 million by 2029.
- Canada experiences a 4.5% CAGR, driven by increased biomedical research funding and institutional investment in imaging infrastructure.
- Canada's strong academic research ecosystem and pharmaceutical sector support sustained demand for advanced preclinical imaging technologies.
- Canada is expected to see growing adoption of multimodal and software-enhanced imaging solutions through 2029.
Preclinical Imaging Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | NUCLEAR IMAGING SYSTEMS (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5% from 2024 to 2029 |
| Largest Segment | PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES (End User) |
| Market Size Base Year (Billions) | ~USD 4 (2024) |
| Revenue Forecast (Billions) | ~USD 5.1 (2029) |
| Segments Covered | Product, Type, Application, End User |
Canada Preclinical Imaging Market Report Segmentation
4 segment dimensions are covered across the global market.
By Product
- Imaging Systems
- Reagents
- Software
By Type
- Barium-Based Contrast Agents
- Bioluminescence Imaging Systems
- Fluorescence Imaging Systems
- Gadolinium-Based Contrast Agents
- Gallium-67-Based Spect Probes
- Gastrografin-Based Contrast Agents
- Gold Nanoparticles
- Iodine-131-Based Spect Probes
- Iodine-Based Contrast Agents
- Iron-Based Contrast Agents
- Magnetic Particle Imaging Systems
- Manganese-Based Contrast Agents
- Micro-Ct Systems
- Micro-Mri Systems
- Micro-Ultrasound Systems
- Nuclear Imaging Systems
- Optical Imaging Systems
- Other Optical Imaging Systems
- Other Spect Probes
- Photoacoustic Imaging Systems
- Technetium-99M-Based Spect Probes
- Thallium-201-Based Spect Probes
By Application
- Cardiology
- Immunology & Inflammation
- Infectious Diseases
- Neurology
- Oncology
- Other Applications
By End User
- Academic & Research Centers
- Imaging Centers
- Other End Users
- Pharmaceutical & Biotechnology Companies
CANADA: PRECLINICAL IMAGING MARKET, BY END USER, 2023–2029
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH CENTERS | 31.5 | 33.2 | 35.1 | 37 | 39 | 41.2 | 43.4 | 5.5 |
| IMAGING CENTERS | 17.7 | 18.8 | 19.9 | 21 | 22.3 | 23.6 | 25 | 5.9 |
| OTHER END USERS | 7.9 | 8.2 | 8.5 | 8.9 | 9.2 | 9.6 | 10 | 4.1 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 139.9 | 147.1 | 154.8 | 162.8 | 171.2 | 180.1 | 189.4 | 5.2 |
| TOTAL | 197 | 207.3 | 218.2 | 229.7 | 241.8 | 254.5 | 267.8 | 5.3 |
Target Audience
- Pharmaceutical Companies : Canadian and international pharma firms need market intelligence to optimize preclinical research investments, identify technology partnerships, and plan facility expansions in Canada.
- Medical Device Manufacturers : Imaging equipment and technology providers require Canada-specific market data to develop localized sales strategies, understand regulatory pathways, and identify institutional buyers.
- Research Institutions : Canadian universities, research hospitals, and biomedical centers use market insights to justify equipment purchases, secure funding, and benchmark their imaging capabilities against peers.
- Investment and Venture Capital : Investors evaluating opportunities in Canadian life sciences and biotech sectors need market sizing and growth projections to assess portfolio companies and funding decisions.
- Government and Policy Bodies : Canadian health agencies, research councils, and policy makers require market data to inform funding priorities, research infrastructure investments, and competitive positioning strategies.
Key Companies in the Canada Preclinical Imaging Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| ANALOGIC CORPORATION | United States | Private Company | MRI,PET,SPECT, |
| XILINX, INC. | United States | Private Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| GUERBET GROUP | France | InvalidIdentifier | PET,SPECT,MRI, |
| BRUKER CORPORATION | United States | Public Company | MRI,PET,SPECT, |
| REVVITY, INC. | United States | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
| OPTISCAN IMAGING LTD. | Australia | Public Company | Optical Imaging (Bioluminescance),PET,SPECT, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and life sciences sector.
ANALOGIC CORPORATION
Analogic Corporation is a United States-based private company founded in 1967 with 1,510 employees, specializing in medical and aerospace technology solutions.
XILINX, INC.
Xilinx, Inc. is a United States-based private company founded in 1984 with 4,890 employees, operating in the semiconductor and programmable logic industry.
GUERBET GROUP
Guerbet Group is a France-based company in the medical imaging and pharmaceutical sector.
BRUKER CORPORATION
Bruker Corporation is a United States-based public company founded in 1960 with 11,085 employees, providing scientific instruments and analytical solutions.
REVVITY, INC.
Revvity, Inc. is a United States-based public company founded in 1937 with 11,000 employees, operating in the life sciences and diagnostics industry.
OPTISCAN IMAGING LTD.
Optiscan Imaging Ltd. is an Australia-based public company founded in 1994 with 9 employees, specializing in optical imaging technology.
Reasons to Buy this Report
- Canada-Specific Market Sizing : Access precise valuation data for Canada's preclinical imaging market with verified 2024 baseline ($20.2M) and 2029 forecasts ($25.2M), enabling accurate budget allocation and investment planning.
- Regional Growth Insights : Understand Canada's 4.5% CAGR trajectory relative to global 5% growth, identifying unique market dynamics, funding patterns, and adoption rates specific to Canadian research institutions.
- Institutional Landscape Analysis : Gain intelligence on adoption patterns across Canadian academic institutions, research hospitals, and pharmaceutical facilities to identify partnership and expansion opportunities.
- Competitive Positioning : Benchmark your organization against Canadian market trends and competitor strategies to optimize product offerings, pricing, and go-to-market approaches for the Canadian research sector.
- Investment Decision Support : Leverage Canada-focused market data to support funding decisions, R&D investments, and strategic planning for companies targeting the Canadian biomedical research and pharmaceutical sectors.
Frequently asked questions
What is the current size of Canada's preclinical imaging market?
Canada's preclinical imaging market is valued at $20.2 million in 2024 and is expected to reach $25.2 million by 2029.
What is the growth rate of Canada's preclinical imaging market?
Canada's preclinical imaging market is growing at a compound annual growth rate of 4.5% from 2024 to 2029.
Which sectors drive demand for preclinical imaging in Canada?
Canada's academic research institutions, pharmaceutical companies, contract research organizations, and biotech firms are primary drivers of preclinical imaging demand.
What imaging technologies are most adopted in Canada?
Canada shows increasing adoption of multimodal imaging systems, optical imaging, microCT, and advanced imaging software platforms for translational research.
How does Canada's market compare to North America?
Canada represents a significant portion of the North American preclinical imaging market, with steady growth supported by government research funding and institutional collaboration.
RESEARCH METHODOLOGY
This market research study utilized extensive secondary sources, directories, and databases to identify and collect information relevant to this technical, market-oriented, and financial analysis of the preclinical imaging market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to gather and verify critical qualitative and quantitative information, as well as to assess market prospects. The size of the preclinical imaging market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was employed to identify and collect information relevant to the comprehensive, technical, market-oriented, and commercial study of the preclinical imaging market. It was also used to obtain important information about key players, market classification, and segmentation according to industry trends, as well as key developments related to market and technology perspectives, down to the most detailed level. A database of the key industry leaders was also prepared using secondary research.
Primary Research
Extensive primary research was conducted after acquiring a basic understanding of the global preclinical imaging market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (hospital personnel, department heads, hospital directors, corporate personnel) and supply side (such as C-level and D-level executives, technology experts, software developers, marketing and sales managers, among others) across five major regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Breakdown of Primary Interviews
Note: Tiers are defined based on the total revenues of companies. As of 2024, Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the global preclinical imaging market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- Key players in the global preclinical imaging market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports and regulatory filings, data books of major market players, and interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global preclinical imaging market were determined by using secondary sources and verified through primary sources.
- All key macroindicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get validated and verified quantitative and qualitative data.
- The gathered market data was consolidated and added with detailed inputs and analysis and presented in this report.
Global Preclinical Imaging Market: Bottom-up and Top-down Approach
Data Triangulation
After arriving at the overall market size, from the market size estimation process explained above, the preclinical imaging market was split into segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the preclinical imaging market.
Market Definition
Preclinical imaging involves the application of molecular imaging for the assessment of anatomical, physiological, and functional parameters in live animal models during preclinical studies. Preclinical imaging systems and reagents are utilized to visualize living animals in order to assess the safety and efficacy of novel drug procedures or other medical treatments for human applications. During preclinical studies, a variety of different imaging modalities are utilized, such as optical imaging systems, nuclear imaging systems (micro-PET and micro-SPECT), micro-MRI, micro-ultrasound systems, and micro-CT imaging systems.
Stakeholders
- Preclinical Imaging Instrument Manufacturers, Suppliers, and Imaging Software Providers
- Pharmaceutical and Biotechnology Companies
- Preclinical Imaging Reagent Manufacturers and Suppliers
- Contract Research Organizations (CROs)
- Research and Development (R&D) Companies
- Government Research Laboratories
- Independent Research Laboratories
- Government and Independent Regulatory Authorities
- Medical Research Laboratories
- Academic Medical Institutes and Universities
- Market Research and Consulting Service Providers
Report Objectives
- To define, describe, and forecast the preclinical imaging market by product type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
-
To analyze the opportunities in the market for stakeholders and provide details of
the competitive landscape for preclinical imaging market leaders - To profile the key players in the market and comprehensively analyze their market shares and core competencies
-
To forecast the size of the market segments with respect to five main regions:
North America, the Asia Pacific, Europe, Latin America, and the Middle East & Africa - To track and analyze competitive developments, such as partnerships, acquisitions, product launches & approvals, and expansions
- To benchmark players within the preclinical imaging market using the Competitive Evaluation Matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering
Get the Full Preclinical Imaging Market Report
Full forecast, segment splits, and company analysis for all Preclinical Imaging Market.
- US Preclinical Imaging Market
- Germany Preclinical Imaging Market
- UK Preclinical Imaging Market
- France Preclinical Imaging Market
- Italy Preclinical Imaging Market
- Spain Preclinical Imaging Market
- Japan Preclinical Imaging Market
- China Preclinical Imaging Market
- India Preclinical Imaging Market
- Brazil Preclinical Imaging Market
- Mexico Preclinical Imaging Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
